Healthcare >> CEO Interviews >> October 12, 2001
DR. W. SCOTT HARKONEN is President, Chief Executive Officer and
Chairman of the Board of Directors of InterMune, Inc. Dr.
Harkonen has more than 18 years of experience in the
biotechnology industry and is well known and respected by the
investment community. In March 2000, he led InterMune through a
successful IPO, an $80 million private placement in August 2000,
a $287 million public offering in July 2001 and a $111 million
secondary public offering in March 2002. He has also played key
roles in obtaining FDA marketing approval of several
biopharmaceutical products. Prior to founding InterMune in 1998,
Dr. Harkonen served as Senior Vice President of Product
Development and Operations for Connetics Corporation. He is
Chairman of the Board of Directors of Exhale Therapeutics, Inc.,
a member of the Board of Directors of Origen Therapeutics, Inc.,
and a member of the Biotechnology Industry Organization's
Governing Board. Dr. Harkonen received his Medical degree from
the University of Minnesota and an MBA from the Haas School of
Business at the University of California at Berkeley. Profile
Dr. Harkonen: InterMune is a commercial-stage biotechnology company
dedicated to developing innovative products for the treatment of
